Spotify Apple Youtube

Category: GLP-1s

All Podcast Categories
S4-40 - Review of Paris NASH 2023

S4-40 – Review of Paris NASH 2023

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for an exciting episode that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. Surf on to learn much more from what always pans out to be an incredibly in-depth and insightful event.

September 13, 2023
S4-37 - Focus on the Role of Allied Health and Strengthening NASH Education

S4-37 – Focus on the Role of Allied Health and Strengthening NASH Education

This week, Surfing NASH looks back at a Season 3 episode that remains particularly relevant in light of recent stories on new nomenclature and therapeutic developments for liver disease. An all-star panel of liver nurses and advanced nurse practitioners join Louise Campbell and Stephen Harrison to explore the myriad ways allied health experts can play a broader role in NASH education and patient management.

August 16, 2023
S4-35.4 - Looking Forward at the SurfingNASH Program

S4-35.4 – Looking Forward at the SurfingNASH Program

The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation hones in on what the audience can expect and look forward to learn more about in the coming months.

August 6, 2023
S4-34.5 - GLP-1s and Lean Muscle Loss

S4-34.5 – GLP-1s and Lean Muscle Loss

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This final conversation continues on the subject of evaluating the GLP-1 drug class and its potential impact on lean muscle loss. The final question of Season 4, Episode 34 considers the big picture scope of what has been learned in the last month that might affect research or conceptual thinking going forward.

July 30, 2023
S4-34.4 - Pemvidutide and the Importance of the Actual GLP-1-to-Glucagon Impact Ratio

S4-34.4 – Pemvidutide and the Importance of the Actual GLP-1-to-Glucagon Impact Ratio

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation considers results from the Phase 2b study for the dual GLP-1/glucagon agonist pemvidutide, which wanders into the importance of the actual GLP-1-to-glucagon impact ratio, potentially significant safety signals that remain to be fully studied, and the subject of how much lean muscle mass these agents produce.

July 30, 2023
S4-34 - Drug Development Stories from EASL and ADA: Part 2

S4-34 – Drug Development Stories from EASL and ADA: Part 2

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. The session explores a range of topics around the subject of drug development, including notes on orals versus injectables, diabetes medications with potential in the NASH space, new clinical trial data, different drug classes and much more.

July 26, 2023
Stay In Touch
Apple Spotify Youtube

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.

Learn More